Pulse Biosciences Reports Breakthrough Results for nsPFA Catheter in Atrial Fibrillation Treatment

Pulse Biosciences Unveils Promising Data on Nanosecond PFA Catheter for Atrial Fibrillation Treatment

Pulse Biosciences, Inc. presents significant findings from a first-in-human feasibility study involving its Nanosecond Pulsed Field Ablation™ (nsPFA™) technology at the 30th Annual AF Symposium 2025. The study assesses the safety and efficacy of the Nanosecond PFA 360° Cardiac Catheter System, designed specifically for treating atrial fibrillation (AF). This pioneering research involves 77 patients, treated by a team of six investigators, including notable figures in the field such as Dr. Vivek Reddy and Prof. Petr Neuzil. Initial results from the first 30 patients show a remarkable 100% acute success rate in achieving conduction block, along with a pulmonary vein isolation (PVI) success rate of 92.4%, indicating the catheter's effectiveness in managing AF.

The procedural details further underscore the system's efficiency. The average total PVI ablation time is recorded at just 11.6 minutes, with overall procedure and fluoroscopy times being 88.3 minutes and 6.9 minutes, respectively. These results suggest that the Nanosecond PFA Catheter not only meets safety benchmarks but also significantly reduces the time required for AF ablation procedures. While the study reports one serious adverse event, a cardiac perforation, and two minor complications, all incidents were resolved without lasting effects, supporting the catheter’s safety profile.

The live case transmission during the symposium showcases the catheter's rapid capabilities in achieving pulmonary vein isolation in conjunction with the Abbott Ensite X System, further validating its practical application in clinical settings. CEO Paul LaViolette highlights the potential of the nsPFA technology to revolutionize AF ablation practices by enhancing both safety and efficiency. Pulse Biosciences is poised to take the next steps in clinical validation, planning to initiate an Investigational Device Exemption (IDE) study later this year, paving the way for broader adoption of this innovative technology.

In related developments, Pulse Biosciences continues to focus on advancing its unique technologies to address unmet medical needs in electrophysiology. The successful preliminary outcomes from the feasibility study position the company favorably within the competitive landscape of cardiac ablation therapies. As the company moves forward with its IDE study, it aims to solidify its role as a key player in the evolving field of atrial fibrillation treatment.